MedTrace Logo

A Study to Efficacy and Safety of CWP-0403 in Type 2 Diabetes Mellitus Patients

NCT01529528 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 117

Last updated 2013-01-04

No results posted yet for this study

Summary

This trial is to evaluate the efficacy and safety of CWP-0403 at 100 mg or 200 mg twice daily compared with placebo in type 2 diabetic patients with inadequate glycemic control by diet therapy or combination of diet and exercise therapy.

Conditions

Interventions

DRUG

Anagliptin

Anagliptin 100mg, tablet, BID

DRUG

Anagliptin

Anagliptin 100mg, tablet, BID

DRUG

Placebo of Anagliptin

Placebo of Anagliptin 100mg, tablet, BID

Sponsors & Collaborators

Principal Investigators

  • Sung Woo Park, M.D., PhD · Kangbuk Samsung Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-05-31
Primary Completion
2012-09-30
Completion
2012-11-30

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01529528 on ClinicalTrials.gov